Escitalopram
Based on 13 publication(s) in Google Scholar
Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.89%
- CAS No.: 128196-01-0
- Formule: C20H21FN2O
- Masse moléculaire:324.39
-
Stockage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-B0176A
Sertraline hydrochloride -
HY-B0196
Venlafaxine -
HY-B0168A
Milnacipran hydrochloride -
HY-15414
Vortioxetine -
HY-14258AR
Escitalopram oxalate (Standard) -
HY-122272
Paroxetine -
HY-14546
Aripiprazole -
HY-B0161
Duloxetine -
HY-B0103
Fluvoxamine -
HY-B0168B
Levomilnacipran hydrochloride -
HY-17364
Temozolomide -
HY-B0176AR
Sertraline hydrochloride (Standard)
Publications Citing Use of MedChemExpress (MCE) Escitalopram
More- Adv Sci (Weinh). 2026 Jul 23:e76755.
- Phytomedicine. 2023 Dec:121:155083. [Abstract]
- Brain Behav Immun. 2026 Jan 26:134:106471. [Abstract]
- Transl Psychiatry. 2025 Feb 17;15(1):54. [Abstract]
- Geroscience. 2026 Mar 5. [Abstract]
- Int Immunopharmacol. 2025 Feb 6:147:113969. [Abstract]
- Mol Neurobiol. 2022 May;59(5):2855-2873. [Abstract]
- Brain Sci. 2025 Feb 24;15(3):236. [Abstract]
- J Clin Psychopharmacol. 2021 Sep-Oct;41(5):525-533. [Abstract]
- PLoS One. 2025 Aug 18;20(8):e0326134. [Abstract]
- bioRxiv. 2026 May 29.
- Brain Mechanisms. 2025 Nov 21.
- SSRN. 2024 Oct 14.
Activité biologique
Description
IC50 & Target
Ki: 0.89 nM (serotonin transporter), 10500 nM (DAT), 8150 nM (NET)[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| COS-7 | IC50 |
4.6 μM
Compound: S-1
|
Allosteric modulation at wild-type human SERT site S2 expressed in african green monkey COS7 cells assessed as inhibition of [3H]citalopram dissociation at 30 uM by scintillation counting analysis
Allosteric modulation at wild-type human SERT site S2 expressed in african green monkey COS7 cells assessed as inhibition of [3H]citalopram dissociation at 30 uM by scintillation counting analysis
|
[PMID: 24237160] |
In Vivo
Chronic administration of Escitalopram (daily; drinking water for a total of 4 months) significantly reduces plaque load by 28% and 34% at 2.5 and 5 mg/d, respectively [4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats[3]
-
Dosage:10 mg/kg
-
Administration:I.p.; daily for 28 days
-
Result:Could selectively decrease phosphorylated tau accumulation in the hippocampus of stressed rats and could distinctly alleviate the hyperactivity of the HPA axis in both depressive and resistant rats.
-
Animal Model:APP-PS1 hemizygous female mice (4 months of age)[4]
-
Dosage:2.5-5 mg/kg
-
Administration:Daily; drinking water for a total of 4 months
-
Result:At both doses significantly reduced plaque burden within the brains of these mice compared to littermate controls that drank only water. Hippocampal plaque load was significantly reduced by 28.7% and 34.4 % for ESC 2.5 mg/day and 5 mg/day, respectively.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 128196-01-0
-
Appearance Oil
-
Masse moléculaire 324.39
-
Formule C20H21FN2O
-
Color Colorless to light yellow
-
SMILES
FC1=CC=C([C@@]2(CCCN(C)C)C(C=CC(C#N)=C3)=C3CO2)C=C1
-
Synonyms
(S)-Citalopram; (S)-(+)-Citalopram
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
-
Phytomedicine
Ginsenoside Rb1 protects hippocampal neurons in depressed rats based on mitophagy-regulated astrocytic pyroptosis. [Abstract]2023 Dec:121:155083. PMID: 37722244 -
Brain Behav Immun
Depression-related chronic stress promotes ovarian cancer progression via metabolic dysfunction and IRF1-mediated immune suppression. [Abstract]2026 Jan 26:134:106471. PMID: 41605304 -
Transl Psychiatry
Association of escitalopram-induced shifts in gut microbiota and sphingolipid metabolism with depression-like behavior in wistar-kyoto rats. [Abstract]2025 Feb 17;15(1):54. PMID: 39962083 -
Geroscience
2026 Mar 5. PMID: 41781498 -
Int Immunopharmacol
Innovative role of the antidepressant imipramine in esophageal squamous cell carcinoma treatment: Promoting apoptosis and protective autophagy. [Abstract]2025 Feb 6:147:113969. PMID: 39764996 -
Mol Neurobiol
Ginsenoside Rg1 Reduced Microglial Activation and Mitochondrial Dysfunction to Alleviate Depression-Like Behaviour Via the GAS5/EZH2/SOCS3/NRF2 Axis. [Abstract]2022 May;59(5):2855-2873. PMID: 35230663 -
Brain Sci
The pCREB/BDNF Pathway in the Hippocampus Is Involved in the Therapeutic Effect of Selective 5-HT Reuptake Inhibitors in Adult Male Rats Exposed to Blast Traumatic Brain Injury. [Abstract]2025 Feb 24;15(3):236. PMID: 40149758 -
J Clin Psychopharmacol
Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People. [Abstract]2021 Sep-Oct;41(5):525-533. PMID: 34121064 -
PLoS One
Untargeted metabolomics reveals quinic acid as the kiwifruit component that affects brain activity in mice. [Abstract]2025 Aug 18;20(8):e0326134. PMID: 40824948 -
-
-
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (308.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.71 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.71 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (282 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Zhang, P., et al., Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbon itrile) analogues at monoamine transporters. J Med Chem, 2010. 53(16): p. 6112-21. [Content Brief]
[2]. Pastoor, D. and J. Gobburu, Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol, 2014. 10(1): p. 121-8. [Content Brief]
[3]. Wu C , et al. Escitalopram alleviates stress-induced Alzheimer's disease-like tau pathologies and cognitive deficits by reducing hypothalamic-pituitary-adrenal axis reactivity and insulin/GSK-3β signal pathway activity. Neurobiol Aging. 2018;67:137-147. [Content Brief]
[4]. Cirrito JR, et al. Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model. Neurology. 2020;95(19):e2666-e2674. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0827 mL | 15.4135 mL | 30.8271 mL | 77.0677 mL |
| 5 mM | 0.6165 mL | 3.0827 mL | 6.1654 mL | 15.4135 mL | |
| 10 mM | 0.3083 mL | 1.5414 mL | 3.0827 mL | 7.7068 mL | |
| 15 mM | 0.2055 mL | 1.0276 mL | 2.0551 mL | 5.1378 mL | |
| 20 mM | 0.1541 mL | 0.7707 mL | 1.5414 mL | 3.8534 mL | |
| 25 mM | 0.1233 mL | 0.6165 mL | 1.2331 mL | 3.0827 mL | |
| 30 mM | 0.1028 mL | 0.5138 mL | 1.0276 mL | 2.5689 mL | |
| 40 mM | 0.0771 mL | 0.3853 mL | 0.7707 mL | 1.9267 mL | |
| 50 mM | 0.0617 mL | 0.3083 mL | 0.6165 mL | 1.5414 mL | |
| 60 mM | 0.0514 mL | 0.2569 mL | 0.5138 mL | 1.2845 mL | |
| 80 mM | 0.0385 mL | 0.1927 mL | 0.3853 mL | 0.9633 mL | |
| 100 mM | 0.0308 mL | 0.1541 mL | 0.3083 mL | 0.7707 mL |
Escitalopram Related Classifications
HY-14258 Related Classifications
Powered by Bioz